Loading
Low-intensity chemotherapy that strips chemical 'off' switches (methyl groups) from DNA so silenced genes can be read again. The mainstay for older patients with AML and high-risk MDS, especially combined with venetoclax.
Azacitidine and decitabine (approved 2004-06) extend survival in higher-risk MDS and were the only option for AML patients unfit for intensive chemotherapy until venetoclax-azacitidine (VIALE-A, 2020) roughly doubled responses and became the standard, now available fully orally. They are given in outpatient cycles for as long as they work; 'HMA failure' defines a population with very poor outcomes where menin inhibitors, IDH inhibitors and trials of new agents are focused. Response can take several cycles, so early stopping is a common error.
Showing the molecule this term concerns: Azacitidine.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax.
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Azacitidine, Venetoclax, Myelodysplastic syndromes / neoplasms (MDS).
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax.
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Azacitidine.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia in older or unfit patients, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares IPSS-R and IPSS-M (myelodysplastic syndrome risk scores), Secondary and therapy-related acute myeloid leukaemia, Acute myeloid leukaemia in older or unfit patients, Azacitidine.
Shares Higher-risk myelodysplastic syndromes, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares IDH1- and IDH2-mutated acute myeloid leukaemia, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.